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ABSTRACT
The primary hyperaldosteronism, an endocrine 
disease increasingly identified in cats, is characterized by adrenal 
gland dysfunction that interferes with the renin-angiotensin-
aldosterone system, triggering the hypersecretion of aldosterone. 
Pathophysiological consequences of excessive aldosterone 
secretion are related to increased sodium and water retention, 
and increased excretion of potassium, which induce hypertension 
and severe hypokalemia, respectively. The most common 
clinical findings in cats include: polydipsia, nocturia, polyuria, 
generalized weakness, neck ventroflexion, syncope, anorexia, 
weight loss, pendulous abdomen and blindness. Diagnosis is based 
on the evidence of hormonal hypersecretion with suppression of 
renin release, imaging and histopathological evaluation of adrenal 
glands. Treatment may be curative with adrenalectomy, in cases 
of unilateral disease, or conservative, through administration 
of aldosterone antagonists, potassium supplementation and 
antihypertensives. Prognosis varies from fair to good with the 
appropriate therapy. This article reviews the main aspects of 
primary aldosteronism in cats, providing the clinician with 
important information for the diagnosis of this disease.
Key words: feline medicine, endocrinology, adrenocortical 
disease, hypertension.
RESUMO
O hiperaldosteronismo primário, doença endrócrina 
cada vez mais identificada em felinos, caracteriza-se pela 
disfunção da glândula adrenal com interferência no sistema renina-
angiotensina-aldosterona, desencadeando a hipersecreção de 
aldosterona. As consequências da secreção excessiva de aldosterona 
estão relacionadas com o aumento da retenção de sódio e água e 
aumento da excreção de potássio, que ocasionarão, respectivamente, 
hipertensão arterial sistêmica e hipocalemia grave. O diagnóstico 
é realizado com base na comprovação da hipersecreção hormonal 
com supressão da liberação de renina, além de exames de imagem 
e avaliação histopatológica da adrenal. O tratamento pode ser 
curativo, com a adrenalectomia, em enfermidades unilaterais, 
ou conservativo, por meio de antagonistas da aldosterona, 
suplementação de potássio e anti-hipertensivos. O prognóstico é 
bom e reservado com a terapia apropriada.
Palavras-chave: medicina felina, endocrinologia, enfermidade 
adrenocortical, hipertensão.
INTRODUCTION
First described  in  humans  in 
1955, primary hyperaldosteronism, also called 
Conn syndrome, is an adrenocortical disorder 
characterized by autonomous adrenal hypersecretion 
of aldosterone. Initially considered to be rare, 
hyperaldosteronism is found in approximately 6% 
of all hypertensive human patients and accounts for 
11% of those with hypertension non- responding 
to therapy (FOGARI et al., 2007). The first case in 
cats was reported in 1983 and currently, though little 
known and diagnosed, it is considered an important 
adrenocortical disease in the species (BISGNANO 
& BRUYETTE, 2012).
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Aldosterone plays important roles both 
in the modulation of vascular tone and in the 
central nervous system function. Mineralocorticoid 
receptors have been identified in non-epithelial 
tissues such as heart fibroblasts, endothelial cells, 
vascular smooth muscle cells and brain. Experiments 
indicate that increased aldosterone concentrations 
are associated with increased sympathetic excitatory 
responses and elevated blood pressure. Aldosterone 
is considered pro-inflammatory and pro-fibrotic 
in blood vessels periphery and plays a key role 
in vascular remodelling and vasoconstriction, 
thus leading to endothelial dysfunction. Persistent 
hypertension in primary aldosteronism is  therefore 
a consequence of the synergic effects of  sodium 
and fluid retention, increased sympathetic tone, 
endothelial dysfunction and increased total 
peripheral resistance (JEPSON, 2011).
Endocrine physiology of aldosterone
Target organs and tissues
Aldosterone is a steroid hormone with 
strong mineralocorticoid activity. It was previously 
thought to be produced only in the adrenal glands; 
recent studies have shown its production by other 
tissues including heart, brain and blood vessels, in 
which it presents both  autocrine and paracrine action 
(CONNELL et al., 2008).
The circulating aldosterone, whose classical 
targets are kidney epithelium, colon and salivary 
glands, overpasses the plasma membrane of such 
tissues and binds to the cytoplasmic mineralocorticoid 
receptor. Although this receptor presents equal affinity 
for cortisol and aldosterone, the mineralocorticoid 
receptors in these tissues enzymatically convert cortisol 
to cortisone, which has little affinity to the receptor, 
ensuring the availability of mineralocorticoid receptors 
for the circulating aldosterone (DJAJADININGRAT-
LAANEN et al., 2011).
Additionally, aldosterone affects other 
epithelial and non-epithelial tissues that contribute to 
the homeostasis of blood pressure, including cardiac 
tissue. Aldosterone increases blood pressure both by 
the expanding the extracellular fluid, and by increasing 
peripheral vascular resistance (CONNELL et al., 2008). 
As demonstrated in humans, long-term excessive 
mineralocorticoids can trigger microangiopathy, 
fibrosis and proliferation of endothelium and smooth 
muscle in tissues such as the heart and kidneys.
Regulation of aldosterone secretion
Aldosterone works by increasing the 
excretion of potassium and hydrogen and resorption 
of sodium and chloride in the distal convoluted tubules. 
Through this mechanism, it regulates systemic blood 
pressure and homeostasis of extracellular fluid in 
response to hemodynamic and electrolyte changes 
(SCHULMAN, 2010). 
Its secretion is primarily regulated by 
the renin-angiotensin-aldosterone system and the 
extracellular concentrations of potassium. In addition 
to these mechanisms, there is evidence that aldosterone 
secretion is also influenced by the adrenocorticotropic 
hormone (ACTH), natriuretic peptides and certain 
neurotransmitters. In spite of the significant difference in 
plasma concentrations of aldosterone observed  before 
and after administration of synthetic ACTH (DECLUE 
et al., 2011), none of these compounds was proven to 
directly or indirectly regulate the secretion of aldosterone 
(DJAJADININGRAT-LAANEN et al., 2011).
Potassium has a direct effect on the zona 
glomerulosa of the adrenal glands for the secretion 
of aldosterone. Hyperkalemia stimulates aldosterone 
secretion by depolarization of the zona glomerulosa 
cells and hypokalemia inhibits such depolarization. 
Sodium (Na+) and potassium (K+) ions are 
extremely important and are directly involved in 
establishing the resting membrane potential. Low 
serum potassium concentrations prevent the cell 
from exercising its action potential thus leading to 
muscle weakness. The nerve cell remains in idle state 
and can not perform the ion exchange necessary for 
impulse conduction and muscle tone.
Through the signaling of kidney 
baroreceptors located in the afferent arterioles, 
juxtaglomerular apparatus cells increase or reduce 
the renin secretion in response to decreased or 
increased circulating blood volume or renal blood 
flow, respectively. The baroreceptors have the function 
of regulating blood pressure; when blood pressure is 
decreased, kidney baroreceptors are activated and 
sympathetic activity is increased, resulting in increased 
heart rate and peripheral vasoconstriction. 
Sympathetic stimulation acts directly 
on the macula densa, a group of modified cells in 
the distal tubules near the end of the loop of Henle 
and closely associated with juxtaglomerular cells. 
The concentration of sodium in the tubular lumen is 
monitored by the macula densa cells, and its reduction 
can trigger communication between the macula densa 
and juxtaglomerular cells, resulting in renin release. 
This released renin is responsible for cleavage of 
angiotensinogen, produced by hepatic metabolism, in 
angiotensin I, an inactive peptide which is hydrolyzed in 
the kidneys to angiotensin II by angiotensin converting 
enzyme (ACE) (SCHULMAN, 2010).
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Besides its vasoconstrictor effect, 
angiotensin II stimulates aldosterone secretion. 
Moreover, circulating concentrations of renin, 
angiotensin II, and aldosterone are all increased when 
blood flow to the kidneys is reduced, thus leading to 
increased sodium retention, increased extracellular 
fluid and low concentration of extracellular potassium 
because of urine losses. Once homeostasis has 
been restored, renin production is reduced and, 
consequently, so does the concentration of aldosterone 
(SCHULMAN, 2010).
Metabolism of aldosterone 
Little is known about the metabolism of 
aldosterone in cats. The liver is often regarded as the 
most important site of steroid hormones conjugation 
and inactivation. In cats, cortisol, estradiol 
and progesterone are mainly excreted via bile 
(GRAHAM & BROWN, 1996). Due to the structural 
similarity, it is expected that the same would occur 
with aldosterone. According to SYME et al. (2007), 
urinary excretion of the free form of aldosterone in 
cats is about 77 times lower than in humans and seven 
times lower when compared to dogs.
Etiology and pathophysiology of hyperaldosteronism
Two pathophysiological mechanisms 
can lead to hypersecretion of aldosterone. The 
reduction in effective arterial blood volume 
caused by heart failure, kidney disease or severe 
hypoproteinemia, activates the renin-angiotensin-
aldosterone system. This physiological response 
is called secondary hyperaldosteronism 
or hyperreninemic hyperaldosteronism 
(DJAJADININGRAT-LAANEN et al., 2011).
In the primary or hyporeninemic 
hyperaldosteronism, autonomous hypersecretion of 
aldosterone is held by neoplastic tissue, adrenocortical 
adenomas or adenocarcinomas, or by nodular 
hyperplasia of the zona glomerulosa of the adrenal 
cortex, also known as primary hyperaldosteronism or 
non neoplastic hyperaldosteronism. In contrast, the 
secretion of aldosterone in these situations is associated 
with suppressed renin activity (SCHULMAN, 2010).
Pathophysiological consequences of 
excessive aldosterone secreted are related to the 
increase in sodium and water retention, and increased 
potassium excretion, which can trigger systemic arterial 
hypertension and severe hypokalemia, respectively. 
Furthermore, as soon as potassium is shifted to the 
extracellular compartment, hydrogen ions are moved 
intracellularly, thus leading to metabolic alkalosis 
(DJAJADININGRAT-LAANEN et al., 2011).
In humans, six different primary 
hyperaldosteronism subtypes have been identified, 
including familial hyperaldosteronism. In contrast 
to what is observed in humans, in which the primary 
bilateral idiopathic hyperaldosteronism (60-65% of 
cases), and aldosterone secretory adenoma (30-35% 
of cases) represent the majority of cases (YOUNG, 
2003; YOUNG, 2007), in cats, hyperaldosteronism 
is mostly attributed to adenomas or adenocarcinomas 
of adrenal glands (DJAJADININGRAT-LAANEN et 
al., 2011). Of 25 cases in cats with histopathological 
confirmation described in the literature, 13 were related 
to carcinoma, seven to unilateral adenomas, two to 
bilateral adenomas and three to bilateral hyperplasia 
(DJAJADININGRAT-LAANEN et al., 2011).
DeCLUE et al. (2005) reported one case 
of adenocarcinoma in a cat, with the adrenal glands 
secreting significant amounts of both aldosterone and 
progesterone. Young (2003) reported adrenocortical 
cancer as part of a recognized syndrome in humans, 
known as multiple endocrine neoplasia (MEN), in 
which, in the presence of autosomal dominance, 
the patient develops tumors in endocrine organs, 
especially pancreas, thyroid, and pituitary. In another 
case reported the cat presented adrenal adenoma, 
insulinoma and parathyroid adenoma (REIMER 
et al., 2005). Despite the data in the literature, 
DJAJADININGRAT-LAANEN et al. (2011) 
suggested that the occurrence of adrenocortical 
hyperplasia may be greater than that reported in cats 
and suggested that histopathological examination 
should be essential to determine the cause of the 
primary hyperaldosteronism in cats, even though it is 
rarely performed.
Although not identified until the present 
time, it is believed that some stimulating factor, 
probably a pituitary peptide present in the circulation, 
is responsible for adrenocortical hyperplasia (JAVADI 
et al., 2005). The idiopathic form of the disease can 
lead to incomplete suppression of renin, while in the 
neoplastic form there is a complete suppression (ASH 
et al, 2005; JAVADI et al., 2005; DJAJADININGRAT-
LAANEN et al., 2011). In cats presenting incomplete 
suppression of renin, the primary hyperaldosteronism 
becomes an important mediator of the progression 
of kidney failure. This occurs because of the two 
circulating mediators of fibroproliferative destruction 
and vascular changes, aldosterone and angiotensin II 
(JAVADI et al., 2005). 
According to JAVADI et al. (2005), 
chronic kidney failure has been related to 
tubulointerstitial and glomerular injury as well as 
the excessive accumulation of extracellular matrix 
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in the kidney. The extracellular matrix accumulation 
may be mediated by a number of factors, including 
angiotensin II. Its action is believed to stimulate  both 
renal interstitial fibrosis and mesangial, glomerular 
endothelial and tubular epithelial hyperplasia and 
hypertrophy. Regarding aldosterone, JAVADI et 
al. (2005) reported its contribution to renal injury 
by promoting vascular fibrosis and thrombosis. 
In addition, many cats may present evidence of 
cardiovascular damage secondary to hypertension 
because of increased intravascular volume, such as 
murmur, cardiomegaly evidenced by radiographic 
evaluation and ventricular hypertrophy evidenced 
by echocardiography (DECLUE et al., 2005).
In humans, the cardiovascular effects of 
aldosterone hypersecretion are well understood 
(GIACCHETTI et al., 2009); in cats, however, 
the role of the primary hyperaldosteronism in the 
development or progression of heart diseases has 
not been determined (SCHULMAN, 2010). Care 
should be taken in cases where the hypersecretion 
of aldosterone to the cardiovascular system 
is observed, as in many patients, especially 
geriatric ones, hypertension, hypokalemia, and 
azotemia or evidence of cardiovascular changes 
are misattributed to chronic kidney failure or 
heart failure as primary disorders rather than 
the direct effect of primary aldosteronism 
(DJAJADININGRAT-LAANEN et al., 2011).
Clinical presentation
Cats diagnosed with primary 
aldosteronism are mostly geriatrics, although 
the disturb had already been identified in cats 
younger than five years (SCHULMAN, 2010). 
From 40 confirmed or suspected cases of primary 
hyperaldosteronism reported, the average age was 13 
years (DJAJADININGRAT-LAANEN et al., 2011). 
Apparently there is no predilection for gender or 
breed (SCHULMAN, 2010).
Primary hyperaldosteronism was 
reported in 24 domestic shorthair  cats, in three 
domestic longhair cats, two British Shorthairs, and 
one individual of each of the following breeds: 
Siamese, Persian, Tonkinese, Burmese, Burmilla 
(DJAJADININGRAT-LAANEN et al., 2011). 
Weakness, of sudden or insidious onset, is the most 
common clinical manifestation, followed by cervical 
ventroflexion related to hypokalemic polymyopathy, 
that occurs most commonly with potassium 
concentrations close to 2.5mmol/L-1 (EGER et al., 
1983; MACKAY et al., 1999; ASH et al., 2005; 
REIMER et al, 2005).
Potassium is the major intracellular 
electrolyte and the relationship between its 
intracellular and extracellular levels is the main 
determinant of the electric potential of the 
membranes; any significant change in extracellular 
potassium concentration can therefore have 
effects not only on metabolic functions, but also in 
nerve conduction, with muscular repercussions; 
hypokalemic polymyopathy is a reflection of 
this. Hind limbs weakness, episodic spasticity 
of forelimbs, plantigrade positioning, impaired 
jumping, flaccid paresis associated to hyporeflexia, 
dysphagia, respiratory distress, lethargy, and mental 
depression have been described (ASH et al., 2005; 
DJAJADININGRAT-LAANEN et al., 2011). From 
33 feline cases reported by SCHULMAN (2010), 
blindness due to retinal detachment or intraocular 
bleeding as a consequence of systemic hypertension 
was observed in 11 animals.
Other deleterious effects of hypertension 
include myocardial hypertrophy and kidney damage 
(DECLUE et al., 2005). Polyuria, polydipsia, 
polyphagia or anorexia, urinary incontinence or 
nocturia, weight loss, and diarrhea are other reported 
clinical manifestations (SCHULMAN, 2010). Physical 
examination may reveal a palpable mass in the 
hypogastric region, pronounced muscular atrophy, the 
skin fragility syndrome, systolic murmur and irregular 
heartbeat (BISIGNANO & BRUYETTE, 2012).
According to a review of 40 cats diagnosed 
with the disorder (DJAJADININGRAT-LAANEN et 
al., 2011), hypertension was observed in 31 of 37 
cats submitted to blood pressure assessment; ocular 
changes, including hyphema, mydriasis, increased 
tortuosity of the retinal vessels, edema and retinal 
detachment, were observed in 10 of 19 animals 
submitted to ophthalmologic evaluation; hypokalemic 
polymyopathy was observed in 19 of 40 cases; signs 
of congestive heart failure was present in one cat, and 
no abnormalities were reported in two patients by the 
first physical assessment.
Regarding laboratory findings in cats, 
moderate to severe hypokalemia is typically 
found, although in the early course of the disease 
the concentrations are within the reference range 
(DECLUE et al., 2005; JAVADI et al., 2005). Sodium 
levels are generally normal or slightly increased and 
indicate a proportional water absorption in relation 
to the tubular absorption of sodium, triggered by 
aldosterone (SCHULMAN, 2010). If hypokalemic 
polymyopathy is observed, the levels of creatine 
kinase (CK) are markedly increased (AHN, 1994). 
This is explained as severe hypokalemia can lead to 
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an acute muscular injury, which triggers the release of 
extremely toxic components into the circulation, most 
notably myoglobin and CK (GOTO et al., 2009).
Because of the potential to precipitate 
or worsen an existing chronic renal injury, the 
cats may also present isosthenuria and increased 
serum creatinine and the concentrations of nitrogen 
compounds (EGER et al., 1983; ASH, 2005). 
Furthermore, proteinuria is a common finding due to 
both the direct action of aldosterone hypersecretion 
and hypertension (JAVADI et al., 2005). Although 
no study has effectively demonstrated its prevalence, 
metabolic alkalosis can be observed in patients with 
primary hyperaldosteronism since extracellular 
potassium translocation leads to hydrogen ions 
moving into the intracellular compartment 
(DJAJADININGRAT-LAANEN et al., 2011).
Primary hyperaldosteronism in humans 
may be associated with metabolic syndrome, 
characterized by insulin resistance, inadequate 
function of beta cells, circulating pro-inflammatory 
proteins and prothrombotic tendency (FALLO et 
al., 2006; SCHULMAN, 2010). Although there 
is no parameter established in feline medicine, 
DJAJADININGRAT-LAANEN et al. (2011), reported 
in their review that all four cats with specified glucose 
determination were hyperglycemic.
Diagnosis
Aldosterone: plasma renin ratio
In cats, the gold standard to differentiate 
the primary hyperaldosteronism from the secondary 
hyperaldosteronism is the aldosterone: renin 
ratio, being 0.3 to 3.8 the established reference 
value (JAVADI et al., 2004; JAVADI et al., 2005). 
Thus, cats with adrenocortical tumors have very 
high plasma aldosterone activity and, in general, 
completely suppressed plasma renin activity, since 
the secretion is independent of the stimulation of 
the renin-angiotensin-aldosterone system (JAVADI 
et al., 2005). In the case of bilateral hyperplasia, 
however, the obtained plasma renin activity may be 
slightly increased or within the upper reference limits 
(DJAJADININGRAT-LAANEN et al., 2011).
Care must be taken in obtaining the 
samples to ensure the accuracy of the test, p.e. the 
obtainment of appropriate amount (>4mL) and 
immediate freezing after centrifugation. The reference 
ranges for plasma renin activity vary widely between 
laboratories, which complicates the interpretation 
and standardization of the test (DJAJADININGRAT-
LAANEN et al., 2011). Moreover, few laboratories 
offer the plasma renin test, which often requires the 
clinician to use the assessment of aldosterone activity 
as a single test (DECLUE et al., 2005). JAVADI et al. 
(2004) determined a reference value of 80-450pmol 
L-1 (28.8 to162.2pg ml-1) for plasma aldosterone 
activity from studies in healthy cats, and reported 
that neither stress nor body condition  affected the 
concentrations. Nevertheless, the same authors 
recommend that plasma aldosterone activity should 
always be based on serum potassium concentrations, 
as hypokalemia is decisive for reduced aldosterone 
secretion. Thus, an aldosterone activity at or above 
the laboratory reference values is inappropriate in 
hypertensive or hypokalemic cats (JAVADI et al., 
2004; LO et al., 2014.).
Urinary aldosterone: creatinine ratio
The assessment of the urinary aldosterone 
to creatinine ratio was recently investigated in cats. 
Although the amount of excreted aldosterone through 
urine in cats is smaller than in humans or dogs 
(SYME et al., 2007), the ratio can be determined and 
the sample is both easy to obtain and representative 
of the aldosterone circulation during the whole period 
of the collected urine production (SCHULMAN, 
2010). This has been shown to be a practical and 
noninvasive method in the diagnosis of primary 
hyperaldosteronism in cats when combined with the 
suppression induced by salt or fludrocortisone acetate 
(DJAJADININGRAT-LAANEN et al., 2013). This 
drug was shown to cause a significant reduction on 
urinary aldosterone to creatinine ratio in healthy 
cats, but not in an animal with confirmed primary 
hyperaldosteronism.
Other tests
The adrenocorticotropic hormone (ACTH) 
stimulates the production of aldosterone and may be 
used to evaluate adrenal mineralocorticoid production 
(BISIGNANO & BRUYETTE, 2012). Exogenous 
ACTH causes reliable increase in aldosterone 
secretion and a recommended IV dose of 125mg 
ACTH per cat has been used, followed by blood 
sample collection 60 to 75 minutes after the hormone 
administration (DECLUE et al., 2011). Despite 
this possibility of ACTH use, BISIGNANO & 
BRUYETTE (2012) concluded that such a test is of 
questionable utility.
An ideal test based on the suppression of 
aldosterone production in normal cats, but presenting 
little or no effect on those patients with primary 
hyperaldosteronism, would be the best method to 
confirm that hyperactivity of zona glomerulosa is 
the responsible for the increased activity of plasma 
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aldosterone (BISIGNANO & BRUYETTE, 2012). 
In a study by DJAJADININGRAT-LAANEN et 
al. (2013) the fludrocortisone suppression test 
was effective to exclude the diagnosis of primary 
hyperaldosteronism in cats presenting plasma 
aldosterone: renin ratio within the reference range. 
This test should be performed in cats with plasma 
aldosterone: renin ratio between 7.5x10-9 and 
46.5x10-9 ; fludrocortisone should be given at 0.05mg 
kg-1 12h-1 for 4 days.
The ratio is determined in the morning 
urine before, during and after the fourth day of 
administration; a suppression lower than 50% 
indicates inadequate secretion of aldosterone. The 
fludrocortisone suppression test cannot predict the 
etiology of the disease and before performing the test, 
blood pressure of the animal should be evaluated; 
hypertension was not observed in this study. Potassium 
levels should be assessed before and during the test, as 
fludrocortisone can lead to hypokalemia. Some tests are 
already available in human medicine, p.e. the captopril 
stimulation test, the saline infusion test and the oral 
administration of sodium test (DJAJADININGRAT-
LAANEN et al., 2011).
Imaging
Imaging tests, aiming on checking the 
laterality of the disease (essential in guiding the 
choice of therapy), should be performed in all 
patients in which primary hyperaldosteronism is 
suspected, specially when screening tests indicate 
abnormal regulation of aldosterone secretion. 
The clinical and laboratory suspicion must 
coexist, as changes in the image not necessarily 
corresponding to hyperaldosteronism but to the 
other kind of hormone producing or non producing 
lesion may occur. In these cases, surgery may be 
unnecessary or even lead to death, for example in 
the case of a pheochromocytoma that is operated 
without adequate pharmacological preparation 
(BISIGNANO & BRUYETTE, 2012).
In cats, the abnormalities observed 
during ultrassonographic examination in patients 
with primary hyperaldosteronism may vary from 
the presence of calcification and masses to changes 
in echogenicity of the adrenal glands (MACKAY 
et al., 1999; ASH et al., 2005). Both computed 
tomography and magnetic resonance imaging 
can be used to improve the image obtained from 
the adrenal glands in cats (ASH et al., 2005). In 
a study performed by JAVADI et al. (2005), from 
11 cats diagnosed with hyperaldosteronism, only 
two exhibited normal appearance of the adrenal 
glands on ultrasound or CT scan and all the others 
presented minor visible abnormalities.
Abnormalities in adrenal glands may still 
correspond to cortisol or progesterone secreting 
masses, pheochromocytomas or nonfunctional 
masses and the finding of abnormal adrenal 
glands do not necessarily imply hypersecretion of 
aldosterone. For this reason, imaging evaluation is 
only performed after confirming hyperaldosteronism 
in humans (DECLUE et al., 2005).
Treatment and prognosis
For cats with unilateral primary 
aldosteronism with no evidence of metastasis, 
adrenalectomy is the therapy of choice and is 
curative for both adenoma and adenocarcinoma 
with signs of hypokalemia or hypertension, 
with resolution of the clinical manifestations 
eliminating additional postoperative therapy (ASH 
et al., 2005; ROSE et al, 2007; LO et al., 2014). 
In human patients, in which aldosterone is secreted 
by adenomas, the control of blood pressure after 
adrenalectomy is achieved in 50-60% of cases 
(DUESBERG & PETERSON, 1997). 
Post operative complications may occur 
and include sepsis, bleeding and thromboembolism 
(DECLUE et al., 2005). These complications were 
reported in 8 of 18 surgical cases in cats, 6 of them 
being fatal (MACKAY et al., 1999; RIJNBERK et 
al., 2001; ASH et al., 2005; DECLUE et al., 2005).
Drug therapy with administration of 
spironolactone, potassium supplementation and 
antihypertensive agents is required in many 
cats, especially those presenting idiopathic 
hyperaldosteronism. The reported survival time 
in cats with conservative therapy ranges from 
several months up to years (ASH et al., 2005). 
Spironolactone, an aldosterone receptor antagonist 
in the distal convoluted tubules and renal collecting 
ducts, promotes potassium retention and sodium 
excretion. The initial dose of 2mg kg-1 every 12 
hours may be increased up to a maximum of 4mg 
kg-1, above which it may cause anorexia, diarrhea 
and emesis. Potassium supplementation, preferably 
oral, is required in refractory cases. The medication 
of choice for persistent hypertension is amlodipine, 
a calcium channel blocker, at an initial dose of 0.1mg 
kg-1 every 24 hours (BISIGNANO & BRUYETTE, 
2012; DJAJADININGRAT-LAANEN et al., 2011).
Mainly because of non-selective 
affinity of spironolactone for androgen, estrogen 
and progesterone receptors in humans, a new 
generation of aldosterone antagonists, eplerenone, 
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began to be used in human patients with primary 
hyperaldosteronism (KARAGIANNIS et al., 2008). 
This medication has not been tested in veterinary 
medicine. The prognosis for cats with bilateral 
adrenal hyperplasia, despite the relative effectiveness 
of drug therapy, is not as good when compared to 
patients with adrenocortical cancer who underwent 
surgical treatment, which have better prognosis.
CONCLUSION
Primary hyperaldosteronism is probably 
the most common adrenocortical disease in cats. In any 
feline patient, especially geriatric and hypertensive 
patients, the disease should be investigated. If 
hyperaldosteronism is suspected, plasma aldosterone 
concentrations should be evaluated and confronted 
with serum potassium levels. The patient should be 
then submitted to the ultrasonographic examination; 
even though it is not a precise exam, it may be useful 
to  determine the adrenocortical laterality.
Due to the common association between 
hypokalemia/hypertension and chronic kidney 
disease, hyperaldosteronism is often not considered 
as a differential diagnosis, pushing such patients away 
from appropriate therapy. Moreover, blood pressure 
is poorly monitored in clinical practice, which 
contributes to the under-diagnosis of the disease. 
With the spreading of this technique, however, a 
considerable increase in the number of reported 
cases is expected in the next years, when a greater 
knowledge regarding the disease in cats should be 
available, especially concerning diagnosis.
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